Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
Respir Investig ; 57(2): 126-132, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30552072

RESUMEN

BACKGROUND: Cigarette smoking in patients with asthma leads to poor symptom control. As patients who are current smokers have been excluded from enrollment in many clinical trials on asthma, there are few reports on the treatment in current smokers with asthma. In this study, we aimed to assess how respiratory physicians manage asthma in current smokers in Japan. METHODS: Respiratory physicians in 16 Japanese hospitals answered a questionnaire on treatment for patients with asthma between December 2014 and February 2015. Medical records were reviewed for 1756 patients with asthma. RESULTS: The mean patient age was 61.1 years, and 62.9% of the patients were female. A total of 102 patients (5.8%) were current smokers, and 546 patients (31.1%) were former smokers. Long-acting muscarinic antagonists (LAMA) were prescribed more frequently for current smokers with asthma than for former smokers and never smokers with asthma (10.8% vs 4.6%, p = 0.01, 10.8% vs 3.8%, p < 0.01). In contrast, macrolides were prescribed more frequently for former smokers and never smokers with asthma than for current smokers with asthma (7.7% vs 1.0%, p = 0.01, 6.4% vs 1.0%, p = 0.03). Triple therapy, i.e., inhaled corticosteroids, long-acting beta agonists, and LAMA concomitantly, was prescribed for current smokers with asthma more frequently than for former smokers and never smokers with asthma (9.8% vs 4.0%, p = 0.01, 9.8% vs 3.3%, p < 0.01). CONCLUSIONS: According to this survey, current smokers with asthma received more intensive therapy, including LAMA, than did former smokers with asthma.


Asunto(s)
Asma/tratamiento farmacológico , Macrólidos/administración & dosificación , Antagonistas Muscarínicos/administración & dosificación , Prescripciones/estadística & datos numéricos , Fumadores , Corticoesteroides/administración & dosificación , Agonistas Adrenérgicos beta/administración & dosificación , Adulto , Anciano , Preparaciones de Acción Retardada , Quimioterapia Combinada , Femenino , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios , Adulto Joven
2.
Am J Clin Pathol ; 134(4): 613-20, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20855643

RESUMEN

Previous studies showed that apoptotic epithelial cells were involved in the pathogenesis of idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP); however, little is known about apoptosis in chronic hypersensitivity pneumonitis (HP). This study was performed to examine whether apoptosis has a role in chronic HP. We performed immunohistochemical studies for p53, p21, Fas, Fas ligand, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling methods on surgical lung specimens. The expression of Fas and Fas ligand was up-regulated in UIP-like lesions compared with nonspecific interstitial pneumonia (NSIP)-like lesions. The expression of p53 and p21 on epithelial cells increased significantly in UIP-like lesions compared with fibrotic NSIP-like lesions and in fibrotic NSIP-like lesions compared with normal lung tissues. These results confirm that apoptotic epithelial cells are present in chronic HP as seen in IPF. Augmented epithelial apoptosis may contribute much more to UIP-like lesions than to NSIP-like lesions in chronic HP.


Asunto(s)
Alveolitis Alérgica Extrínseca/patología , Apoptosis/fisiología , Fibrosis Pulmonar Idiopática/patología , Pulmón de Criadores de Aves/patología , Proteína Ligando Fas/análisis , Humanos , Pulmón/patología , Proteína p53 Supresora de Tumor/análisis , Receptor fas/análisis , Quinasas p21 Activadas/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA